The Pharmaceutical Post

FROM CHALLENGE TO SOLUTION:
The future of Eye Drug Delivery

PHARMACEUTICAL PACKAGING AND SUSTAINABILITY:
Can polymers be part of the solution?

No.25
January-February-March

www.thepharmaceuticalpost.com

Interview

by Cindy H. Dubin

NEMERA

Séverine Duband,
STRATEGY & MARKETING DIRECTOR, OPHTHALMICS AND RESPIRATORY BUSINESS UNIT

SAFE AND SUSTAINABLE PFMD EYE CARE

Nemera plays a leading role in enabling safe, user-friendly preservative-free delivery across ophthalmic therapies. Through its Novelia® platform, the company offers a multidose device that prevents microbial growth over treatment duration and eliminates the need for preservatives in formulations. Séverine Duband, Strategy & Marketing Director, Ophthalmics and Respiratory Business Unit, Nemera, describes Nemera's end-to-end combination product services, including analytical testing, design verification, human-factors validation, and regulatory strategy to help pharma partners accelerate development in the ocular space.

Please explain how Novelia makes daily administration easier and safer for patients.

SÉVERINE DUBAND: Features like a human-centric design, configurable performance, and microbial protection make Novelia a reference for safe, comfortable, and sustainable PFMD eye care. Novelia makes daily administration easier, safer, and more comfortable. The soft, ergonomic bottle and patented blue nozzle tip help users target the eye with greater accuracy, while our technology maintains safety and performance

drop after drop. Together, these features enhance trust and comfort—helping patients adhere to their therapy and experience better quality of life.

How do care givers benefit from Novelia?

S.D.: For care providers, Novelia simplifies treatment management and supports better clinical outcomes by improving dose precision and patient adherence. Consistent one-drop delivery helps ensure the prescribed therapeutic dose is achieved every time, while the preservative-free design reduces the risk of ocular irritation and drop-related discontinuation—issues that often complicate chronic eye-care management. The device's proven microbiological integrity – supported by stability studies conducted on the combination product - also gives healthcare professionals confidence in long-term sterility and product safety across the treatment duration.

Can Novelia accommodate a wide panel of ophthalmic formulations?

S.D.: Yes, we offer:

• **Bottles:** LDPE (5–15 mL) and PP (11 mL) in standard or soft versions, plus BFS (Blow-Fill-Seal) options allowing unique shapes.



Novelia®, Nemera's multi-dose eyedropper for preservative-free formulations.

• **Caps:** standard and vented versions, available in multiple colors.

• **Range of Drop** sizes tuned to formulation viscosity.

• **Flow control:** PureFlow 10, 200 and 1500 options ensure optimal delivery for very liquid to viscous solutions.

This modularity allows pharma companies to match their drug characteristics, target markets, and regulatory preferences seamlessly.

Please describe a successful partner collaboration.

S.D.: Through continuous innovation and close collaboration with our partners, we aim to make effective eye care accessible and intuitive for every patient. We cannot disclose any customer name, but we are proud to collaborate with a wide range of companies both on OTC and prescription combination products. To ensure a successful go to market and regulatory approval Nemera can offer a range of dedicated services. These services ensure usability, safety, and compliance under real-world and extreme conditions, supporting regulatory submissions and patient safety.
Here are three examples of expertise and know-how brought by Nemera to support customers on their PFMD selection and commercialization.

• **In-use Study – Actuation Force and Drop Size:** Evaluate actuation force and drop size throughout the in-use period to ensure ease of use and dose consistency. Output: Submission-ready report confirming dose uniformity and usability, including visual inspection for drop appearance and device performance.*

• **Microbiological challenge testing on the combination product:** Demonstrate microbiological safety and integrity under real in-use conditions to support regulatory submissions and patient safety. Outcome: Independent, submission-ready report confirming microbiological robustness; enables 'no contamination' or 'microbial safety' claims.

• **Functional assessment of combination product:** Assess device and formulation performance under challenging conditions (temperature extremes, freeze-thaw, high heat). Outcome: Comprehensive, submission-ready report confirming mechanical and microbiological integrity, sterility, and regulatory compliance; short lead times thanks to in-house lab.